ReviewNature reviews. Neurology2011
Integration and analysis of genome-scale data from gliomas.
Review in Nature reviews. Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 99 citations in OpenAlex.
- Selective Cytotoxic and Redox-Associated Effects of Plant-Derived Terpenoids in Human Glioblastoma Cells.Cell biochemistry and biophysics · 2026Article
- Self-Assembled Aza-Boron-Dipyrromethene-Based HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.International journal of molecular sciences · 2023Review
- Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.Cell reports. Medicine · 2023Article
- HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway.British journal of cancer · 2022Article
- Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.Advanced drug delivery reviews · 2022Review
- Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.Cellular & molecular biology letters · 2022Review
- ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody.JCI insight · 2021Article
- The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.Molecular neurobiology · 2021Review
- Article
- Modelling genetic mosaicism of neurodevelopmental disorders in vivo by a Cre-amplifying fluorescent reporter.Nature communications · 2020Article
- Microarray analysis of aberrant microRNA expression patterns in spinal cord gliomas of different grades.Oncology letters · 2020Article
- β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.The Journal of experimental medicine · 2020Article
- E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression.British journal of cancer · 2020Article
- Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.Molecular oncology · 2020Article
- Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q.Journal of Cancer · 2020Article
- TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.British journal of cancer · 2019Article
- Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.Journal of neuro-oncology · 2019Article
- The landscape of the mesenchymal signature in brain tumours.Brain : a journal of neurology · 2019Article
- Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins.Drug delivery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Primary brain tumors are a leading cause of cancer-related mortality among young adults and children. The most common primary malignant brain tumor, glioma, carries a median survival of only 14 months. Two major multi-institutional programs, the Glioma Molecular Diagnostic Initiative and The Cancer Genome Atlas, have pursued a comprehensive genomic characterization of a large number of clinical glioma samples using a variety of technologies to measure gene expression, chromosomal copy number alterations, somatic and germline mutations, DNA methylation, microRNA, and proteomic changes. Classification of gliomas on the basis of gene expression has revealed six major subtypes and provided insights into the underlying biology of each subtype. Integration of genome-wide data from different technologies has been used to identify many potential protein targets in this disease, while increasing the reliability and biological interpretability of results. Mapping genomic changes onto both known and inferred cellular networks represents the next level of analysis, and has yielded proteins with key roles in tumorigenesis. Ultimately, the information gained from these approaches will be used to create customized therapeutic regimens for each patient based on the unique genomic signature of the individual tumor. In this Review, we describe efforts to characterize gliomas using genomic data, and consider how insights gained from these analyses promise to increase understanding of the biological underpinnings of the disease and lead the way to new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.